Date:7/20/2009

----- ----- Total current assets 54,700 50,041 Intangible asset, net 11,806 12,387 Property and equipment, net 11,367 13,238 Marketable securities 1,584 3,145 Other assets 3,335 969 ----- --- Total assets $82,792 $79,780 ======= ======= LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Accounts payable and accrued expenses $12,608 $13,136 Deferred revenue, related party 6,110 5,965 Other current liabilities 1,617 475 ----- --- Total current liabilities 20,335 19,576 Long-term obligations 33,411 17,061 Deferred revenue, related party, net of current portion 33,607 35,790 ------ ------ Total liabilities 87,353 72,427 Stockholders' equity (deficit) (4,561) 7,353 ------ ----- Total liabilities and stockholders' equity (deficit) $82,792 $79,780 ======= =======

    Idenix Pharmaceuticals' Contacts:
    Media: Teri Dahlman (617) 995-9905
    Investors: Amy Sullivan (617) 995-9838

'/>"/>

SOURCE Idenix Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
2. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
3. Idenix Pharmaceuticals Reports First Quarter Financial Results
4. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
5. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
6. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
8. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
9. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
10. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
11. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results